Standard BioTools Inc
LAB
Company Profile
Business description
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Contact
2 Tower Place
Suite 2000
South San FranciscoCA94080
USAT: +1 650 266-6000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
818
Stocks News & Analysis
stocks
What AI means for US software companies’ moats
We’re no longer certain that software firms will outperform over the next decade, but positive outcomes remain possible for names like Salesforce.
stocks
Lower moat ratings on four ASX shares due to AI
We believe AI weakens the competitive advantage of these companies.
stocks
What Q4 US earnings did and didn’t tell us about AI and the outlook for tech shares
Tech saw solid earnings, but there are more questions around which companies will benefit from AI, and which will be hurt.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,823.60 | 16.90 | -0.19% |
| CAC 40 | 7,797.70 | 195.79 | -2.45% |
| DAX 40 | 23,018.07 | 572.96 | -2.43% |
| Dow JONES (US) | 47,501.55 | 453.19 | -0.95% |
| FTSE 100 | 10,129.58 | 155.17 | -1.51% |
| HKSE | 25,408.46 | 348.83 | -1.35% |
| NASDAQ | 22,387.68 | 361.31 | -1.59% |
| Nikkei 225 | 52,728.72 | 2,892.12 | -5.20% |
| NZX 50 Index | 13,098.83 | 519.06 | -3.81% |
| S&P 500 | 6,740.02 | 90.69 | -1.33% |
| S&P/ASX 200 | 8,599.00 | 3.30 | -0.04% |
| SSE Composite Index | 4,096.60 | 27.59 | -0.67% |